Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAM · Nasdaq

Beam Therapeutics Inc. (BEAM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Beam Therapeutics Inc. in 2026. The next earnings report is expected on November 9, 2026.

Earnings calendar

Next earnings date

09 Nov 2026

In 81 days

EPS estimate

-1.16

Revenue estimate

12.5M

Past earnings

04 Aug 2026
EPS actual
-1.18 (-6.7%)
estimate -1.11
Revenue actual
490.0K (-97.0%)
estimate 16.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-0.91 (+11.5%)
estimate -1.03
Revenue actual
31.7M (+189.1%)
estimate 11.0M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
24 Feb 2026
EPS actual
2.33 (+330.8%)
estimate -1.01
Revenue actual
114.1M (+877.9%)
estimate 11.7M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
04 Nov 2025
EPS actual
-1.10 (-6.0%)
estimate -1.04
Revenue actual
9.7M (-14.5%)
estimate 11.3M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Beam Therapeutics missed consensus estimates in its latest earnings report, with EPS of $-1.18 versus an estimate of $-1.1064 and revenue of $490 thousand, which fell 97.0% short of expectations. In the prior quarter both EPS and revenue came in ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
John Evans
Employees
393
IPO date
06 Feb 2020
ISIN
US07373V1052
Website
beamtx.com

Frequently asked questions

When does Beam Therapeutics Inc. (BEAM) next report earnings?

Beam Therapeutics Inc. (BEAM) is scheduled to report earnings on November 9, 2026.

What was Beam Therapeutics Inc.'s most recent earnings date?

Beam Therapeutics Inc. (BEAM) last reported earnings on August 4, 2026.

Where is Beam Therapeutics Inc. stock listed?

Beam Therapeutics Inc. (BEAM) is listed on Nasdaq.